---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-026336"
form_type: "8-K"
ticker: "EWTX"
cik: "0001710072"
company_name: "Edgewise Therapeutics, Inc."
filed_at: "2024-02-22T23:59:59+00:00"
generated_at: "2026-06-05T19:45:00.508160+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Edgewise posts Q4 net loss $0.47/sh; pro-forma cash >$550M; multiple trial readouts in 2024

## Summary
- Net loss for Q4 2023 was $30.1M ($0.47 per share), up from $25.7M ($0.41) in Q3 2023.
- Cash, equivalents and marketable securities $318.4M at Dec 31, 2023; pro-forma >$550M after $231.8M net Jan 2024 offering.
- R&D expenses $27.7M (+$3.9M QoQ); G&A $6.2M (+$0.5M QoQ) as clinical programs advanced.
- Expect CANYON (Becker) data Q4 2024; ARCH 24-month, DUNE, and LYNX dose data in Q2 2024.
- EDG-7500 Phase 1 data and Phase 2 obstructive HCM data expected Q3 2024; FOX trial dosing starts early 2024.

## SEC filing metadata
- accession: 0001104659-24-026336
- form_type: 8-K
- ticker: EWTX
- cik: 0001710072
- company_name: Edgewise Therapeutics, Inc.
- filed_at: 2024-02-22T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1710072/000110465924026336/0001104659-24-026336-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1710072/000110465924026336/tm246960d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-026336
- JSON: https://secwatch.observer/filing/0001104659-24-026336.json
- Plain text: https://secwatch.observer/filing/0001104659-24-026336.txt

## Key facts
- Earnings Releases
  Edgewise Therapeutics, Inc. reported financial results for fourth quarter and full year ended December 31, 2023.
  - Period: fourth quarter and full year ended December 31, 2023
  - Result: reported results
  source text: On February 22, 2024, Edgewise Therapeutics, Inc. issued a press release announcing its financial results for the fourth quarter and full year ended December 31, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1710072/000110465924026336/0001104659-24-026336-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.